Columbia slashes workforce by 42% after US FDA rejection
This article was originally published in Scrip
Executive Summary
After the markets closed on 1 March, Columbia Laboratories revealed that it was cutting 42% of its workforce, reducing its employee head count from 24 to 14, after the US FDA earlier in the week rejected its partner Watson's new drug application (NDA) for its progesterone vaginal gel 8% as a therapy to reduce the risk of preterm birth (scripintelligence, 27 February 2012).